Pituitary Iron Deposition and Endocrine Complications in Patients with β-Thalassemia: From Childhood to Adulthood

References

• Cappellini MD, Cohen A, Porter J, et al. Guidelines for the management of transfusion dependent thalassaemia (TDT). 3rd ed. Nicosia (Cyprus): Thalassaemia International Federation Publication; 2014. p. 17–65.
   Google Scholar
• Mohammadion S, Bazrafshan HR, Sadeghi-Nejad A. Endocrine gland abnormalities in thalassemia major: a brief review. J Pediatr Endocrinol Metab. 2003;16(7):957–964.
   PubMed Web of Science ®Google Scholar
• De Sanctis V, Roos M, Gasser T, et al. Italian working group on endocrine complications in non-endocrine diseases. Impact of long-term iron chelation therapy on growth and endocrine functions in thalassaemia. J Pediatr Endocrinol Metab. 2006;19(4):471–480.
   PubMed Web of Science ®Google Scholar
• Wood JC. Impact of iron assessment by MRI. Hematology Am Soc Hematol Educ Program. 2011;2011:443–450.
   PubMed Web of Science ®Google Scholar
• Perifanis V, Christoforidis A, Vlachaki E, et al. Comparison of effects of different long-term iron-chelation regimens on myocardial and hepatic iron concentrations assessed with T2* magnetic resonance imaging in patients with beta-thalassemia major. Int J Hematol. 2007;86(5):385–389.
   PubMed Web of Science ®Google Scholar
• Au WY, Lam WW, Chu WW, et al. A cross-sectional magnetic resonance imaging assessment of organ specific hemosiderosis in 180 thalassemia major patients in Hong Kong. Haematologica. 2008;93(5):784–786.
   PubMed Web of Science ®Google Scholar
• De Sanctis V, Soliman AT, Elsedfy H, et al. Growth and endocrine disorders in thalassemia: the international network on endocrine complications in thalassemia (I-CET) position statement and guidelines. Indian J Endocrinol Metab. 2013;17(1):8–18.
   PubMedGoogle Scholar
• De Sanctis V, Eleftheriou A, Malaventura C. Thalassaemia International Federation Study Group on Growth and Endocrine Complications in Thalassaemia. Prevalence of endocrine complications and short stature in patients with thalassaemia major: a multicenter study by the Thalassaemia International Federation (TIF). Pediatr Endocrinol Rev. 2004;2(Suppl 2):249–255.
   PubMedGoogle Scholar
• Borgna-Pignatti C, Cappellini MD, De Stefano P, et al. Survival and complications in thalassemia major. Ann N Y Acad Sci. 2005;1054:40–47.
   PubMed Web of Science ®Google Scholar
• Li CK, Luk CW, Ling SC, et al. Morbidity and mortality patterns of thalassaemia major patients in Hong Kong: retrospective study. Hong Kong Med J. 2002;8(4):255–260.
   PubMedGoogle Scholar
• Isik P, Yarali N, Tavil B, et al. Endocrinopathies in Turkish children with beta thalassemia major: results from a single center study. Pediatr Hematol Oncol. 2014;31(7):607–615.
   PubMed Web of Science ®Google Scholar
• De Sanctis V, Pintor C, Gamberini MR, et al. Multicentre study on prevalence of endocrine complications in thalassaemia major. Clin Endocrinol. 1995;42(6):581–586.
   PubMedGoogle Scholar
• Altincik A, Akin M. Prevalence of endocrinopathies in Turkish children with β-thalassemia major: a single-center study. J Pediatr Hematol Oncol. 2016;38(5):389–393.
   PubMed Web of Science ®Google Scholar
• Moayeri H, Oolomi Z. Prevalence of growth and puberty failure with respect to growth hormone and gonadotropins secretion in β-thalassemia major. Arch Iran Med. 2006;9(4):329–334.
   PubMedGoogle Scholar
• Wood JC, Noetzl L, Hyderi A, et al. Predicting pituitary iron and endocrine dysfunction. Ann N Y Acad Sci. 2010;1202:123–128.
   PubMed Web of Science ®Google Scholar
• Noetzli LJ, Panigrahy A, Hyderi A, et al. Pituitary iron and volume imaging in healthy controls. Am J Neuroradiol. 2012;33(2):259–265.
   PubMed Web of Science ®Google Scholar
• Cetincakmak MG, Hattapoglu S, Menzilcioglu S, et al. MRI-based evaluation of the factors leading to pituitary iron overload in patients with thalassemia major. J Neuroradiol. 2016;43(4):297–302.
   PubMed Web of Science ®Google Scholar
• Bozdag M, Bayraktaroglu S, Aydinok Y, et al. MRI assessment of pituitary iron accumulation by using pituitary-R2 in β-thalassemia patients. Acta Radiol. 2018;59(6):732–739.
   PubMed Web of Science ®Google Scholar
• Vogiatzi MG, Macklin EA, Trachtenberg FL, et al.; Thalassemia Clinical Research Network. Differences in the prevalence of growth, endocrine and vitamin D abnormalities among the various thalassaemia syndromes in north America. Br J Haematol. 2009;146(5):546–556.
   PubMed Web of Science ®Google Scholar
• Tzoulis P. Review of endocrine complications in adult patients with β-thalassaemia major. Presented at the 4th Pan-European Conference on Haemoglobinopathies and Rare Anaemias, Athens, Greece, November 7-9 2014. Thalassemia Rep. 2014. 4(3):4871.
   Google Scholar
• Marcon A, Motta I, Taher AT, et al. Clinical complications and their management. Hematol Oncol Clin North Am. 2018;32(2):223–236.
   PubMed Web of Science ®Google Scholar
• Chatterjee R, Bajoria R. New concept in natural history and management of diabetes mellitus in thalassemia major. Hemoglobin. 2009;33(Sup1):S127–S130.
   PubMedGoogle Scholar
• Simcox JA, McClain DA. Iron and diabetes risk. Cell Metab. 2013;17(3):329–341.
   PubMed Web of Science ®Google Scholar
• Tzoulis P, Shah F, Jones R, et al. Joint diabetes thalassaemia clinic: an effective new model of care. Hemoglobin. 2014;38(2):104–110.
   PubMed Web of Science ®Google Scholar
• Kyriakou A, Skordis N. Thalassaemia and aberrations of growth and puberty. Mediterr J Hematol Infect Dis. 2009;1(1):e2009003.
   PubMedGoogle Scholar
• Soliman AT, Khalafallah H, Ashour R. Growth and factors affecting it in thalassemia major. Hemoglobin. 2009;33(Sup1):S116–S126.
   PubMedGoogle Scholar
• Baksi AJ, Pennell DJ. Randomized controlled trials of iron chelators for the treatment of cardiac siderosis in thalassaemia major. Front Pharmacol. 2014;5:217.
   PubMed Web of Science ®Google Scholar
• Carpenter JP, Roughton M, Pennell DJ, the Myocardial Iron in Thalassemia (MINT) Investigators. International survey of T2* cardiovascular magnetic resonance in β-thalassemia major. Haematologica. 2013;98(9):1368–1374.
   PubMed Web of Science ®Google Scholar
• Pennell DJ, Porter JB, Cappellini MD, et al. Deferasirox for up to 3 years leads to continued improvement of myocardial T2* in patients with β-thalassemia major. Haematologica. 2012;97(6):842–848.
   PubMed Web of Science ®Google Scholar
• Karakas Z, Yilmaz Y, Bayramoglu Z, et al. Magnetic resonance imaging during management of patients with transfusion-dependent thalassemia: a single-center experience. Radiol Med. 2018;123(8):572–576.
   PubMed Web of Science ®Google Scholar